News & Views

Telix Manufacturing Solutions Belgium Delivers First GMP-Grade Commercial Doses

News,

Telix today announces that its Telix Manufacturing Solutions (TMS) facility in Brussels South (Seneffe), Belgium, has produced its first Good Manufacturing Practice (GMP)-grade commercial radiopharmaceutical doses and delivered them to…

Telix’s Illuccix® PSMA-PET Imaging Agent Approved in Italy

News,

Telix today announces that its prostate cancer PET imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), has been granted marketing authorization in Italy by the AIFA for…

Illuccix® Prostate Cancer PSMA-PET Imaging Agent Approved in Belgium

News,

Telix today announces that its prostate cancer PET imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing authorization by AFMPS for the detection and…

Telix Precision Medicine Announces AlFluor™ Radiochemistry Platform

News,

Telix today announces it has launched a novel PET radiochemistry solution based on 18F-aluminium fluoride (AlF), named…

Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025

News,

Telix today announces five abstract presentations and two satellite symposia featuring its developmental theranostic programs and commercial products at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual…

Illuccix® Prostate Cancer PSMA-PET Imaging Agent Approved in Greece

News,

Telix today announces that its prostate cancer PET imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing authorization by the Greek EOF for the…

Telix Launches New Prostate Cancer Imaging Agent, Gozellix®, in U.S.

News,

Telix today announces that its next-generation PSMA-PET imaging agent for prostate cancer, Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), is now commercially available nationally in the United…

Telix’s Illuccix® PSMA-PET Imaging Agent Approved in Germany

News,

Telix today announces that its prostate cancer PET[1] imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), has been granted marketing authorization in Germany by BfArM[2] for the…

Telix’s Illuccix® PSMA-PET Imaging Agent Approved in Portugal

News,

Telix today announces that its prostate cancer PET imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), has been granted marketing authorization in Portugal by INFARMED for the…

Telix Investor Day in New York City on June 11, 2025: Presenting KOLs

News,